Olivia G. Waltner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Olivia G. Waltner has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Scott N. Furlan
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
56 shared publications - April A. Apfelbaum
Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute
50 shared publications - Elizabeth R. Lawlor
Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute
50 shared publications - Emma D. Wrenn
Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children’s Research Institute
50 shared publications - Sami Barna Kanaan
Translational Science and Therapeutics Division, Fred Hutch Cancer Center
33 shared publications - Shruti S. Bhise
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
33 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Multimodal single-cell analyses reveal distinct fusion-regulated transcriptional programs in Ewing sarcoma
Ewing sarcoma (EwS) is a fusion-driven malignancy, peaking in adolescence. Although EwS tumors are driven uniquely by EWS::FLI1 and related fusions, patient outcomes vary greatly. If and how tumor plasticity of EWS::FLI1-regulated transcriptional signatures contributes to disease progression is not known. To address this, we utilized a single-cell co-assay of RNA and chromatin accessibility (ATAC) sequencing to identify gene regulatory networks in EwS. By comprehensively characterizing regulatory elements across cell lines, we identified multiple unique modules of gene regulation. Differential usage and prevalence of these modules was evident across cell lines, associated with distinct epigenetic and transcriptomic signatures, and in specific cases, modifiable by exogenous TGF-β. When we examined primary EwS patient tumors, we observed these same regulatory modules were variably enriched both across and within tumors, highlighting the existence of intratumoral heterogeneity in gene regulatory networks. Our findings demonstrate that multiple, co-existing transcriptional programs shape the phenotypic diversity of EwS and suggest that the balance between these networks may have important implications for clinical outcomes and targeted therapy development.
- 11 November 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Open AccessMultimodal single-cell analyses reveal distinct fusion-regulated transcriptional programs in Ewing sarcoma
Ewing sarcoma (EwS) is a fusion-driven malignancy, peaking in adolescence. Although EwS tumors are driven uniquely by EWS::FLI1 and related fusions, patient outcomes vary greatly. If and how tumor plasticity of EWS::FLI1-regulated transcriptional signatures contributes to disease progression is not known. To address this, we utilized a single-cell co-assay of RNA and chromatin accessibility (ATAC) sequencing to identify gene regulatory networks in EwS. By comprehensively characterizing regulatory elements across cell lines, we identified multiple unique modules of gene regulation. Differential usage and prevalence of these modules was evident across cell lines, associated with distinct epigenetic and transcriptomic signatures, and in specific cases, modifiable by exogenous TGF-β. When we examined primary EwS patient tumors, we observed these same regulatory modules were variably enriched both across and within tumors, highlighting the existence of intratumoral heterogeneity in gene regulatory networks. Our findings demonstrate that multiple, co-existing transcriptional programs shape the phenotypic diversity of EwS and suggest that the balance between these networks may have important implications for clinical outcomes and targeted therapy development.
- Open Access
Multimodal single-cell analyses reveal distinct fusion-regulated transcriptional programs in Ewing sarcoma
Ewing sarcoma (EwS) is a fusion-driven malignancy, peaking in adolescence. Although EwS tumors are driven uniquely by EWS::FLI1 and related fusions, patient outcomes vary greatly. If and how tumor plasticity of EWS::FLI1-regulated transcriptional signatures contribute to disease progression is not known. To address this, we utilized a single-cell co-assay of RNA and chromatin accessibility (ATAC) sequencing to identify gene regulatory networks in EwS. By comprehensively characterizing regulatory elements across cell lines, we identified multiple unique modules of gene regulation. Differential usage and prevalence of these modules was evident across cell lines, associated with distinct epigenetic and transcriptomic signatures, and in specific cases, modifiable by exogenous TGF-β. When we examined primary EwS patient tumors, we observed these same regulatory modules were variably enriched both across and within tumors, highlighting the existence of intratumoral heterogeneity in gene regulatory networks. Our findings demonstrate that multiple, co-existing transcriptional programs shape the phenotypic diversity of EwS and suggest that the balance between these networks may have important implications for clinical outcomes and targeted therapy development. Summary: Multimodal transcriptional analysis reveal how Ewing sarcoma tumors use distinct gene programs, including one linked to TGF-β, to drive cancer behavior and progression.
Open AccessMultimodal single-cell analyses reveal distinct fusion-regulated transcriptional programs in Ewing sarcoma
Ewing sarcoma (EwS) is a fusion-driven malignancy, peaking in adolescence. Although EwS tumors are driven uniquely by EWS::FLI1 and related fusions, patient outcomes vary greatly. If and how tumor plasticity of EWS::FLI1-regulated transcriptional signatures contribute to disease progression is not known. To address this, we utilized a single-cell co-assay of RNA and chromatin accessibility (ATAC) sequencing to identify gene regulatory networks in EwS. By comprehensively characterizing regulatory elements across cell lines, we identified multiple unique modules of gene regulation. Differential usage and prevalence of these modules was evident across cell lines, associated with distinct epigenetic and transcriptomic signatures, and in specific cases, modifiable by exogenous TGF-β. When we examined primary EwS patient tumors, we observed these same regulatory modules were variably enriched both across and within tumors, highlighting the existence of intratumoral heterogeneity in gene regulatory networks. Our findings demonstrate that multiple, co-existing transcriptional programs shape the phenotypic diversity of EwS and suggest that the balance between these networks may have important implications for clinical outcomes and targeted therapy development. Summary: Multimodal transcriptional analysis reveal how Ewing sarcoma tumors use distinct gene programs, including one linked to TGF-β, to drive cancer behavior and progression.
- 8 May 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (19) , 2214-2228
Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graft-versus-host disease
Chronic graft-versus-host disease (cGVHD) remains the leading cause of nonrelapse morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Effective therapeutic agents targeting dysregulated cytokines including interleukin-17 (IL-17) and colony-stimulating factor 1 (CSF-1) have been defined in preclinical models of cGVHD, and efficacy in subsequent clinical trials has led to their recent US Food and Drug Administration approval. Despite this, these agents are effective in only a subset of patients, expensive, difficult to access outside the United States, and used in a trial-and-error fashion. The ability to readily discern druggable, dysregulated immunity in these patients is desperately needed to facilitate the selection of appropriate treatment and to potentially identify high-risk individuals for preemptive therapy. We used single-cell sequencing–based approaches in our informative preclinical cGVHD models to “reverse engineer” temporal IL-17 and CSF-1 signatures in mouse blood that could be used to interrogate patients. We defined distinct, nonintuitive IL-17 and CSF-1 signatures in mouse blood monocytes that could be identified in relevant monocyte populations within 70% of patients at diagnosis of cGVHD and in half of patients at day +100 after HCT who subsequently developed cGVHD. These signatures can now be evaluated prospectively in clinical studies to help delineate potential responder and nonresponders to relevant therapeutics targeting these pathways.
- 8 May 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (19) , 2214-2228
Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graft-versus-host disease
Chronic graft-versus-host disease (cGVHD) remains the leading cause of nonrelapse morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Effective therapeutic agents targeting dysregulated cytokines including interleukin-17 (IL-17) and colony-stimulating factor 1 (CSF-1) have been defined in preclinical models of cGVHD, and efficacy in subsequent clinical trials has led to their recent US Food and Drug Administration approval. Despite this, these agents are effective in only a subset of patients, expensive, difficult to access outside the United States, and used in a trial-and-error fashion. The ability to readily discern druggable, dysregulated immunity in these patients is desperately needed to facilitate the selection of appropriate treatment and to potentially identify high-risk individuals for preemptive therapy. We used single-cell sequencing–based approaches in our informative preclinical cGVHD models to “reverse engineer” temporal IL-17 and CSF-1 signatures in mouse blood that could be used to interrogate patients. We defined distinct, nonintuitive IL-17 and CSF-1 signatures in mouse blood monocytes that could be identified in relevant monocyte populations within 70% of patients at diagnosis of cGVHD and in half of patients at day +100 after HCT who subsequently developed cGVHD. These signatures can now be evaluated prospectively in clinical studies to help delineate potential responder and nonresponders to relevant therapeutics targeting these pathways.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Table 3. RNAseq-derived gene expression data for CD73- and CD73+ A673 and CHLA10 cells.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Table 3. RNAseq-derived gene expression data for CD73- and CD73+ A673 and CHLA10 cells.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Figure S2. CD73+ cells are enriched in EMT and ECM gene expression. Related to Figure 2.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Figure S2. CD73+ cells are enriched in EMT and ECM gene expression. Related to Figure 2.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Table 4. Top 200 markers of NT5E+ cells (by fold change vs. NT5E- cells) from nine EwS cell lines by single cell sequencing.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Table 4. Top 200 markers of NT5E+ cells (by fold change vs. NT5E- cells) from nine EwS cell lines by single cell sequencing.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Table 1. Table of selected reagents and resources used.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Table 1. Table of selected reagents and resources used.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S5 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Figure S5. Patient tumor gene expression microarrays display heterogeneity of expression of NT5E and associated mesenchymal gene signature. Related to Figure 5.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S5 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Figure S5. Patient tumor gene expression microarrays display heterogeneity of expression of NT5E and associated mesenchymal gene signature. Related to Figure 5.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Figure S3. Spatial heterogeneity of CD73+ tumor cells and ECM deposition in additional xenograft and PDX-derived models. Related to Figure 3.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Figure S3. Spatial heterogeneity of CD73+ tumor cells and ECM deposition in additional xenograft and PDX-derived models. Related to Figure 3.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Table 2. 52 genes overlapping between markers of cells with high GO:BP Mesenchymal Development from A673 and CHLA10 single cell sequencing and EWS::FLI1 repressed gene set.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Cancer-associated fibroblast-like tumor cells remodel the Ewing sarcoma tumor microenvironment
Supplemental Table 2. 52 genes overlapping between markers of cells with high GO:BP Mesenchymal Development from A673 and CHLA10 single cell sequencing and EWS::FLI1 repressed gene set.